TLR4 agonist containing adjuvants have been approved as part of several vaccines: Cervarix against cervical cancer, Shingrix against shingles and Fendrix against Hepatitis B. Similarly, a TLR9 agonist is included in another Hepatitis B vaccine, Heplisav-B. Here, TLR9 is linked to cervical carcinoma.